Serum Institute of India makes strategic investment in IntegriMedical
The Serum Institute of India (SII), has announced a strategic investment in IntegriMedical, acquiring a 20% stake in the company. This collaboration aims to advance the development and deployment of Needle-Free Injection System (N-FIS) technology. This partnership aligns with SII’s vision of ‘Health for All’ and IntegriMedical’s mission to ‘Transform Healthcare Globally.’ Together, they aim to provide patient comfort, increase compliance, reduce needle-stick injuries, and enhance the efficacy of liquid medications via needle-free dispersion. IntegriMedical has developed a US-patented Needle-Free Injection System that uses a high-velocity jet stream powered mechanically to administer biologics and drugs effectively. This innovative drug delivery solution aims to alleviate pain during administration, providing needle-phobic patients with a stress-free experience. Read more@ https://themachinemaker.com/news/serum-institute-of-india-makes-strategic-investment-in-integrim